Commentary

Perspective - Reevaluating the Risk for PPHN

Publish date: January 23, 2012

 

This column, Drugs, Pregnancy, and Lactation, appears regularly in Ob.Gyn. News, a publication of Elsevier. Dr. Cohen directs the perinatal psychiatry program at Massachusetts General Hospital, Boston, which provides information about pregnancy and mental health at www.womensmentalhealth.org. He has been a consultant to manufacturers of SSRIs. To comment, e-mail him at obnews@elsevier.com.

Pages

Recommended Reading

Bevacizumab Effective With First-Line Treatment for Ovarian Cancer
MDedge Family Medicine
Investigational Vaccine Prevents Some HSV-1 Genital Disease
MDedge Family Medicine
Preterm Delivery a Risk in Systemic Sclerosis
MDedge Family Medicine
Subclinical Shedding Persists, Despite HSV-2 Therapy
MDedge Family Medicine
Pregnant Women With Lymphoma Can Have Good Outcomes
MDedge Family Medicine
SSRI Use Raises Risk of Persistent Pulmonary Hypertension of the Newborn
MDedge Family Medicine
Abortion Rates Plateau Worldwide; Nearly Half of Abortions Are Unsafe
MDedge Family Medicine
Progesterone Gel Faces FDA Skepticism Over Foreign Data
MDedge Family Medicine
FDA Panel Fails to Recommend Gel to Prevent Preterm Labor
MDedge Family Medicine
Does cervical membrane stripping in women with group B Streptococcus put the fetus at risk?
MDedge Family Medicine